

Tenet Healthcare Corp. (THC)

\$198.76 (Stock Price as of 12/23/2025)

Price Target (6-12 Months): **\$226.00**

Long Term: 6-12 Months

Zacks Recommendation:

Neutral

(Since: 10/06/25)

Prior Recommendation: Outperform

Short Term: 1-3 Months

Zacks Rank: (1-5)

3-Hold

Zacks Style Scores:

VGM: A

Value: A

Growth: A

Momentum: F

Summary

Tenet Healthcare's performance is fueled by increasing revenues per adjusted admissions, while its strategy of acquisitions and alliances expands the scale of its business through inorganic growth. The company's revenue per adjusted admission rose 6.5% year over year in the first nine months of 2025. Net operating revenues from the hospital segment are expected to be within \$16.05-\$16.2 billion in 2025. As of Sept. 30, 2025, USPI had interests in 530 ambulatory surgery centers and 26 surgical hospitals in 37 states. We expect admissions in Same-Hospital to rise 2.4% year over year in 2025. However, rising expenses might put pressure on its margins in the future. Its operating expenses rose 25% year over year in the first nine months of 2025. Its valuation remains a concern at current levels. As such, the stock warrants a cautious stance.

Data Overview

52 Week High-Low	\$222.82 - \$109.82
20 Day Average Volume (sh)	802,848
Market Cap	\$17.5 B
YTD Price Change	57.5%
Beta	1.44
Dividend / Div Yld	\$0.00 / 0.0%
Industry	Medical - Hospital
Zacks Industry Rank	Top 42% (101 out of 243)


Last EPS Surprise	11.1%
Last Sales Surprise	1.0%
EPS F1 Est- 4 week change	0.0%
Expected Report Date	02/11/2026
Earnings ESP	0.0%

P/E TTM	12.8
P/E F1	12.4
PEG F1	0.9
P/S TTM	0.8

Price, Consensus & Surprise⁽¹⁾



Sales and EPS Growth Rates (Y/Y %)⁽²⁾



Sales Estimates (millions of \$)⁽²⁾

	Q1	Q2	Q3	Q4	Annual*
2026	5,437 E	5,461 E	5,524 E	5,700 E	22,122 E
2025	5,223 A	5,271 A	5,289 A	5,378 E	21,161 E
2024	5,368 A	5,103 A	5,122 A	5,072 A	20,665 A

EPS Estimates⁽²⁾

	Q1	Q2	Q3	Q4	Annual*
2026	3.73 E	3.68 E	3.78 E	4.22 E	15.41 E
2025	4.36 A	4.02 A	3.70 A	4.02 E	16.10 E
2024	3.22 A	2.31 A	2.93 A	3.44 A	11.88 A

*Quarterly figures may not add up to annual.

(1) The data in the charts and tables, except the estimates, is as of 12/23/2025.

(2) The report's text, the analyst-provided estimates, and the price target are as of 11/25/2025.

Overview


Founded in 1967 and headquartered in Dallas, TX, Tenet Healthcare Corp., is an investor-owned health care services company, which owns and operates general hospitals and related health care facilities for urban and rural communities in numerous states, and has offices in California and Florida. The company has investments in other health care companies and is one of the largest investor-owned health care delivery systems in the United States.

Tenet Healthcare and its subsidiaries provide healthcare services primarily through general hospitals and related healthcare facilities. Its hospitals offer acute care services, operating and recovery rooms, radiology services, respiratory therapy services, clinical laboratories, and pharmacies; intensive care, critical and coronary care units; physical therapy along with orthopedic, oncology, and outpatient services. The related health care facilities include rehabilitation hospitals, specialty hospitals and long-term care facilities.

As of Dec 31, 2024, the company operated an expansive care network that included 49 hospitals and more than 575 other healthcare facilities, including ambulatory surgery centers, urgent care centers, imaging centers, surgical hospitals, off-campus emergency departments and micro-hospitals through its units, partnerships and joint ventures. Effective fourth-quarter 2023, the company combined its Conifer segment with the Hospital segment and now has two reporting segments: Hospital Operations and Services and Ambulatory Care.

Hospital Segment (78.1% of total segment revenues in 2024): It includes 61 hospitals catering to primarily urban and suburban communities in nine states. The unit also provides a number of services primarily to healthcare providers to assist them in generating sustainable improvements in their operating margins, while also managing patient, physician and employee satisfaction.

Ambulatory Care (21.9%): The company's Ambulatory Care segment includes the operations of its USPI joint venture and its Aspen facilities.



Reasons To Buy:

- ▲ **Organic Growth:** Thanks to growing patient revenue per adjusted admission, the company's top and bottom lines are rising. The metric rose nearly 2% year over year in 2023, then 4% in 2024 and 6.5% year over year in first nine months of 2025. We expect the company to experience a 2.4% YoY increase in admissions in Same-Hospital in 2025. Net operating revenues from the hospital segment for 2025 are forecasted to be within \$16.05-\$16.2 billion. Revenues from Ambulatory Care segments are projected to be within \$5.1-\$5.15 billion. Adjusted EPS is anticipated to be in the range of \$15.93-\$16.26. The company plans to invest in its high-acuity specialty services in the future. It plans to continue allocating more capital to this service line, in a bid to drive organic growth. Demand for its services is expected to increase as the senior population and cases of diseases increase.
- ▲ **Inorganic Growth:** Tenet Healthcare boasts a strong inorganic growth story, thanks to numerous acquisitions, partnerships and strategic alliances, aimed primarily at boosting the scale of business, operating capacity and an expanding geographical presence. It has constantly partnered with industry biggies like Blue Cross Blue Shield of Texas, Cigna, Aetna, UnitedHealth, Humana and so on. The company announced its collaboration with Oracle Fusion Cloud Human Capital Management to simplify and modernize its payroll processes and human resources on Sep 18, 2023. All these initiatives poise the company well for long-term growth. It also signed a new multi-year national contract with Aetna and a multi-year statewide contract with Blue Cross of Texas. In September 2025, it opened a new hospital facility in Florida. In the third quarter of 2025, THC acquired 11 centers and inaugurated 2 de novo centers. Shares of the company have outperformed its industry over the past year.
- ▲ **Divestitures:** Tenet doesn't shy away from divesting its non-core and unprofitable business units to repay debt, maintain financial liquidity and allocate capital to higher-return investments. In February 2024, Tenet divested three hospitals and related operations in South Carolina to Novant Health. By April 2024, it completed the divestiture of two hospitals, affiliated physician practices, and related operations to Adventist Health. Tenet divested four hospitals and related operations in Orange and Los Angeles Counties to UCI Health. In September 2024, it divested five hospitals and related operations in Alabama. In October 2024, Tenet Healthcare sold its 70% stake in Brookwood Baptist Health to Orlando Health for \$910 million, focusing on high-growth areas like ambulatory care.
- ▲ **Solid USPI Segment:** The Ambulatory Care segment comprises the operations of USPI Holding Company, Inc. (USPI). In June 2022, THC purchased the 5% ownership stake of Baylor University Medical Center in the USPI business for \$406 million and consequently owns 100% of USPI's voting stock. The company's performance has been steadily gaining from USPI's performance, continuous buyout of the SCD Centers, buy-ups in multiple surgical hospitals and tuck-in acquisitions. USPI had interests in 530 ambulatory surgery centers and 26 surgical hospitals in 37 states as of Sept. 30, 2025.

Expanding revenues, divestitures, acquisitions and a solid USPI business remain key positives for Tenet Healthcare.

Reasons To Sell:

- ▼ **Rising Expenses:** Tenet Healthcare has experienced high levels of operating expenses in the past few years. Despite the company's cost-management program comprising primarily headcount reductions and the renegotiation of contracts with suppliers and vendors, its operating expenses inched up 1.3% year over year in 2022. The same escalated by 6% in 2023 due to higher salaries, wages and benefits, supplies and other operating expenses. In 2024, its supplies expenses rose nearly 2% YoY. Likewise, in the first nine months of 2025, the operating expenses rose 25% year over year to \$13.3 billion. The growing utilization of resources might push expenses higher in the coming days.
- ▼ **Cash Flow Situation:** The company's net cash from operations declined thrice in the past four years. It decreased 54% and 30.9%, respectively, in 2021 and 2022. Although it witnessed an increase in 2023, it again declined 13.8% in 2024. The metric increased 18.1% in the first nine months of 2025. The broader industry is facing challenges, including the new administration's focus on reducing government spending, which can impact hospitals' profits.
- ▼ **Overvaluation Concerns:** Tenet Healthcare appears overvalued and relatively expensive at its current level. The company's price-to-earnings (P/E) ratio is a notable indicator, and investors may be hesitant to pay an additional premium. Currently, it holds a forward 12-month P/E ratio of 12.91X, higher than the industry average of 11.57X.

Escalating expenses and valuation remain major concerns for the company.

Last Earnings Report

Tenet Q3 Earnings Beats Estimates on Strong Ambulatory Care Unit

Tenet Healthcare reported third-quarter 2025 adjusted earnings per share (EPS) of \$3.70, which surpassed the Zacks Consensus Estimate by 11.1%. The bottom line increased 26.3% year over year.

Net operating revenues advanced 3.2% year over year to \$5.3 billion. The top line beat the consensus mark by 1%.

The quarterly results benefited from higher same-facility revenues, a favorable payer mix and improved acuity, which led to strong performance of the Hospital Operations and Services segment. Facility buyouts boosted the performance of the Ambulatory Care segment. However, the upside was partly offset by rising operating costs, particularly supplies expense.

Inside THC's Q3 Performance

Adjusted net income of \$328 million climbed 16.3% year over year in the quarter under review.

Adjusted EBITDA improved 12.4% year over year to \$1.1 billion, higher than our estimate of \$1 billion. The year-over-year growth was backed by improved same-facility revenues, higher acuity, a favorable payer mix and prudent expense management efforts. Adjusted EBITDA margin of 20.8% improved 170 basis points (bps) year over year.

Total operating costs increased 8.9% year over year to \$4.5 billion in the third quarter due to a higher supplies expense.

Q3 Segmental Details of Tenet Healthcare

Hospital Operations and Services: The segment recorded net operating revenues of \$4 billion, which inched up 0.7% year over year on the back of improved same-hospital admissions, higher acuity and favorable payer mix. The metric beat the Zacks Consensus Estimate by 0.6% and our estimate by 0.8%. Nevertheless, on a same-hospital basis, net patient service revenues grew 7.5% year over year.

Adjusted EBITDA climbed 12.6% year over year to \$607 million in the third quarter, driven by higher same-facility revenues, a favorable payer mix and prudent expense management efforts. The metric surpassed the consensus mark of \$563.8 million and our estimate of \$562.1 million. Adjusted EBITDA margin of 15.1% improved 160 bps year over year.

Ambulatory Care: The segment's net operating revenues rose 11.9% year over year to \$1.3 billion in the quarter under review on the back of improved same-facility net patient services revenues, facility buyouts and expansion of service lines. The metric topped the Zacks Consensus Estimate by 1.1% and our estimate by 3.2%.

Adjusted EBITDA was \$492 million, which advanced 12.1% year over year, attributable to facility buyouts, prudent expense management efforts and solid same-facility net patient service revenue growth. The metric beat the consensus mark of \$473.9 million and our estimate of \$463.1 million. Adjusted EBITDA margin improved 10 bps year over year at 38.6%.

THC's Financial Position (as of Sept. 30, 2025)

Tenet Healthcare exited the third quarter with cash and cash equivalents of \$3 billion, which declined 1.5% from the 2024-end level.

Total assets of \$29.4 billion rose from the figure of \$28.9 billion at 2024-end.

Long-term debt, net of the current portion, amounted to \$13.1 billion, which inched up marginally from the figure as of Dec. 31, 2024. The current portion of long-term debt totaled \$85 million.

Total shareholders' equity of \$4 billion decreased 3.8% from the 2024-end level.

THC generated \$2.8 billion of net cash from operations in the first nine months of 2025, which advanced 18.1% year over year. Free cash flows improved 21.7% year over year to \$2.2 billion in the first nine months of 2025.

THC's Share Repurchase Update

THC bought back common shares worth \$93 million in the third quarter of 2025. As of Sept. 30, 2025, the company had a leftover share repurchase authorization of around \$1.7 billion.

Tenet Raises Outlook for 2025

Net operating revenues are currently expected to be within \$21.15-\$21.35 billion, higher than the earlier view of \$20.95-\$21.25 billion. The midpoint of the revised guidance indicates 2.8% growth from the 2024 figure.

Net operating revenues of the Hospital segment are now forecasted to lie between \$16.05 billion and \$16.2 billion, higher than the prior guidance of \$15.95-\$16.1 billion. The metric at the Ambulatory Care unit is estimated at \$5.1-\$5.15 billion, up from the previous view of \$5-\$5.15 billion.

Adjusted EBITDA is likely to remain between \$4.47 billion and \$4.57 billion for 2025, higher than the prior view of \$4.4-\$4.54 billion. The midpoint of the updated guidance indicates 13% growth from the 2024 figure. Adjusted EBITDA margin is estimated to be in the 21.1-21.4% band compared with the earlier view of 21-21.4%.

FY Quarter Ending 12/31/2024

Earnings Reporting Date	Oct 28, 2025
Sales Surprise	1.02%
EPS Surprise	11.11%
Quarterly EPS	3.70
Annual EPS (TTM)	15.52

Adjusted net income is now projected to be between \$1.45 billion and \$1.48 billion, up from the prior outlook of \$1.415-\$1.475 billion. Adjusted EPS is presently anticipated within \$15.93-\$16.26, up from the earlier view of \$15.55-\$16.21. The midpoint of the revised outlook implies a 35.5% rise from the 2024 figure. Interest expense is still estimated between \$815 million and \$825 million.

Net cash provided by operating activities is now expected to be between \$3.15 billion and \$3.5 billion. Free cash flow is now estimated to remain between \$2.275 billion and \$2.525 billion. Capital expenditures are projected in the range of \$875-\$975 million.

Valuation

Tenet Healthcare's shares are up 70% over the year-to-date period and up 47.4% in the trailing 12 months. Stocks in the Zacks sub-industry are up 32.7%, while the Zacks Medical sector is up 6.4% over the year-to-date period. Over the past year, the Zacks sub-industry is up 15.7% while the sector is down 1.7%.

The S&P 500 index is up 16.4% over the year-to-date period and 14.3% in the past year.

The stock is currently trading at 12.91X forward 12-month earnings, which compares to 11.57X for the Zacks sub-industry, 21.02X for the Zacks sector and 23.15X for the S&P 500 index.

Over the past five years, the stock has traded as high as 18.48X and as low as 5.42X, with a 5-year median of 12.08X. Our Neutral recommendation indicates that the stock will perform in-line with the market. Our \$226 price target reflects 13.56X forward earnings.

The table below shows summary valuation data for THC.

Valuation Multiples - THC					
		Stock	Sub-Industry	Sector	S&P 500
P/E F12M	Current	12.91	11.57	21.02	23.15
	5-Year High	18.48	16.63	23.63	23.81
	5-Year Low	5.42	9.19	17.87	15.73
	5-Year Median	12.08	13.35	20.59	21.21
P/S F12M	Current	0.85	0.71	2.1	5.23
	5-Year High	0.87	0.81	3.4	5.5
	5-Year Low	0.18	0.4	2.01	3.83
	5-Year Median	0.39	0.54	2.63	5.04
P/B TTM	Current	3.26	3.43	3.94	8.34
	5-Year High	8.65	4.68	6.05	9.16
	5-Year Low	1.62	2.31	3.56	6.6
	5-Year Median	2.87	3.4	4.52	8.03

As of 11/24/2025

Source: Zacks Investment Research

Industry Analysis⁽¹⁾ Zacks Industry Rank: Top 42% (101 out of 243)



Top Peers⁽¹⁾

Company (Ticker)	Rec	Rank
Universal Health Ser...(UHS)	Outperform	1
Community Health Sys...(CYH)	Neutral	3
Elevance Health, Inc...(ELV)	Neutral	3
The Ensign Group, In...(ENSG)	Neutral	2
HCA Healthcare, Inc. (HCA)	Neutral	3
Humana Inc. (HUM)	Neutral	3
Acadia Healthcare Co...(ACHC)	Underperform	5
Molina Healthcare, I...(MOH)	Underperform	5

Industry Comparison⁽¹⁾ Industry: Medical - Hospital

	THC	X Industry	S&P 500	ACHC	CYH	UHS
Zacks Recommendation (Long Term)	Neutral	-	-	Underperform	Neutral	Outperform
Zacks Rank (Short Term)	3	-	-	5	3	1
VGM Score	A	-	-	D	A	B
Market Cap	17.47 B	3.20 B	39.09 B	1.30 B	446.03 M	14.20 B
# of Analysts	9	6	22	6	4	7
Dividend Yield	0.00%	0.00%	1.4%	0.00%	0.00%	0.35%
Value Score	A	-	-	A	A	A
Cash/Price	0.17	0.09	0.04	0.09	0.27	0.01
EV/EBITDA	3.99	7.95	14.63	5.67	10.27	7.95
PEG Ratio	0.89	0.87	2.22	3.47	NA	0.77
Price/Book (P/B)	3.02	2.51	3.33	0.42	NA	2.00
Price/Cash Flow (P/CF)	9.42	8.53	15.32	2.86	1.28	8.53
P/E (F1)	12.35	8.68	19.84	6.95	3.70	10.41
Price/Sales (P/S)	0.84	0.84	3.13	0.40	0.04	0.84
Earnings Yield	8.13%	12.00%	5.03%	14.40%	27.02%	9.61%
Debt/Equity	2.27	0.55	0.56	0.73	-8.31	0.55
Cash Flow (\$/share)	21.09	4.93	8.98	4.93	2.52	26.63
Growth Score	A	-	-	D	B	C
Hist. EPS Growth (3-5 yrs)	23.22%	17.06%	8.16%	2.07%	NA	10.91%
Proj. EPS Growth (F1/F0)	35.52%	39.53%	8.50%	-38.48%	NA	31.43%
Curr. Cash Flow Growth	21.87%	8.11%	6.86%	1.46%	8.11%	31.02%
Hist. Cash Flow Growth (3-5 yrs)	11.46%	7.40%	7.48%	10.41%	-7.16%	4.38%
Current Ratio	1.71	1.47	1.18	1.44	1.47	1.03
Debt/Capital	73.47%	39.87%	38.01%	44.03%	NA	35.72%
Net Margin	6.49%	6.49%	12.78%	3.29%	2.60%	8.09%
Return on Equity	25.11%	10.35%	17.00%	7.66%	-6.90%	19.47%
Sales/Assets	0.72	0.82	0.53	0.53	0.92	1.14
Proj. Sales Growth (F1/F0)	2.40%	2.91%	5.83%	4.30%	-0.90%	9.70%
Momentum Score	F	-	-	F	C	D
Daily Price Chg	-0.56%	-0.56%	0.46%	-2.49%	-2.13%	0.28%
1 Week Price Chg	-1.54%	0.91%	1.61%	0.91%	0.62%	2.18%
4 Week Price Chg	-9.02%	-7.20%	2.13%	-14.91%	-7.20%	-6.76%
12 Week Price Chg	-2.11%	-2.11%	3.31%	-43.05%	0.31%	11.17%
52 Week Price Chg	53.23%	4.45%	14.40%	-62.57%	2.55%	25.41%
20 Day Average Volume	802,848	802,848	2,805,434	3,286,770	1,775,743	703,534
(F1) EPS Est 1 week change	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
(F1) EPS Est 4 week change	0.00%	0.00%	0.00%	-13.43%	0.00%	0.00%
(F1) EPS Est 12 week change	1.89%	4.37%	0.67%	-23.46%	359.70%	6.85%
(Q1) EPS Est Mthly Chg	0.00%	0.00%	0.00%	-74.80%	0.00%	0.00%

Analyst Earnings Model⁽²⁾

Tenet Healthcare Corporation (THC)

In \$MM, except per share data

	2022A	2023A	2024A	2025 E			2026E			2027E				
	FY	FY	FY	1QA	2QA	3QA	4QE	FY	1QE	2QE	3QE	4QE	FY	FY
FY Ends December 31st	Dec-22	Dec-23	Dec-24	31-Mar-25	30-Jun-25	30-Sep-25	31-Dec-25	Dec-25	31-Mar-26	30-Jun-26	30-Sep-26	31-Dec-26	Dec-26	Dec-27
Income Statement														
Net Operating Revenue	\$19,174.0	\$20,548.0	\$20,665.0	\$5,223.0	\$5,271.0	\$5,289.0	\$5,378.0	\$21,161.0	\$5,437.0	\$5,460.6	\$5,524.0	\$5,699.9	\$22,121.5	\$23,124.6
Grant Income	\$194.0	\$16.0	\$10.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Equity in Earnings of Unconsolidated Affiliates	\$216.0	\$228.0	\$260.0	\$56.0	\$61.0	\$64.0	\$77.9	\$258.9	\$55.5	\$61.3	\$65.4	\$79.4	\$261.6	\$266.7
Salaries, Wages & Benefits	\$8,844.0	\$9,146.0	\$8,801.0	\$2,119.0	\$2,160.0	\$2,204.0	\$2,216.6	\$8,699.6	\$2,323.7	\$2,321.4	\$2,349.6	\$2,408.2	\$9,403.0	\$9,727.9
Supplies	\$3,273.0	\$3,590.0	\$3,647.0	\$907.0	\$932.0	\$931.0	\$966.2	\$3,736.2	\$938.1	\$951.6	\$969.6	\$994.6	\$3,853.9	\$4,001.6
Other Operating Expenses, Net	\$3,998.0	\$4,515.0	\$4,492.0	\$1,090.0	\$1,119.0	\$1,119.0	\$1,140.8	\$4,468.8	\$1,134.5	\$1,153.1	\$1,159.4	\$1,201.9	\$4,648.9	\$4,837.2
Depreciation and Amortization	\$841.0	\$870.0	\$818.0	\$206.0	\$208.0	\$218.0	\$212.7	\$844.7	\$219.7	\$221.5	\$223.4	\$229.4	\$893.9	\$943.2
Impairment and Restructuring Charges, and Acquisition-Related Costs	\$226.0	\$137.0	\$102.0	\$19.0	\$24.0	\$23.0	\$24.0	\$90.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Litigation and Investigation Costs	\$70.0	\$47.0	\$35.0	\$17.0	\$28.0	(\$11.0)	\$0.0	\$34.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Net Gains on Sales, Consolidation and Deconsolidation of Facilities	(\$1.0)	(\$23.0)	(\$2,916.0)	(\$22.0)	\$38.0	(\$20.0)	\$0.0	(\$4.0)	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Adjusted EBITDA	\$3,469.0	\$3,541.0	\$3,995.0	\$1,163.0	\$1,121.0	\$1,099.0	\$1,132.2	\$4,515.2	\$1,096.2	\$1,095.8	\$1,110.8	\$1,174.6	\$4,477.3	\$4,824.5
Operating Income	\$2,333.0	\$2,510.0	\$5,956.0	\$943.0	\$823.0	\$889.0	\$895.6	\$3,550.6	\$876.4	\$874.3	\$887.4	\$945.2	\$3,583.4	\$3,881.3
Interest Expense	\$890.0	\$901.0	\$826.0	\$204.0	\$206.0	\$206.0	\$205.9	\$821.9	\$211.2	\$211.8	\$213.9	\$220.3	\$857.2	\$895.5
Other Non-Operating Expense (Income), Net	(\$10.0)	(\$19.0)	(\$126.0)	(\$26.0)	(\$25.0)	(\$29.0)	(\$28.1)	(\$108.1)	(\$27.8)	(\$28.1)	(\$28.9)	(\$29.5)	(\$114.3)	(\$119.8)
Loss from Early Extinguishment of Debt	\$109.0	\$11.0	\$8.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Pre-Tax Income	\$1,344.0	\$1,617.0	\$5,248.0	\$765.0	\$642.0	\$712.0	\$717.8	\$2,836.8	\$693.0	\$690.6	\$702.5	\$754.4	\$2,840.5	\$3,105.6
Income Tax	\$344.0	\$306.0	\$1,184.0	\$143.0	\$120.0	\$133.0	\$134.1	\$530.1	\$129.5	\$129.0	\$131.2	\$140.9	\$530.6	\$580.1
Tax Rate	25.6%	18.9%	22.6%	18.7%	18.7%	18.7%	18.7%	18.7%	18.7%	18.7%	18.7%	18.7%	18.7%	18.7%
Non Controlling Interest	\$590.0	\$700.0	\$864.0	\$216.0	\$234.0	\$237.0	\$255.6	\$942.6	\$244.2	\$249.6	\$253.8	\$262.4	\$1,010.0	\$1,067.8
Net Income from Continuing Operations, Adjusted	\$744.0	\$744.0	\$1,162.0	\$414.0	\$369.0	\$328.0	\$347.6	\$1,458.6	\$319.3	\$312.0	\$317.5	\$351.1	\$1,299.9	\$1,457.7
Net Income from Continuing Operations, GAAP	\$410.0	\$611.0	\$3,200.0	\$406.0	\$288.0	\$342.0	\$328.1	\$1,364.1	\$319.3	\$312.0	\$317.5	\$351.1	\$1,299.9	\$1,457.7
Effect of Dilutive Stock , Restricted Stock , Deferred Compensation Units, Convertible Instruments & Dividends on Preferred Stock	(\$8.0)	\$13.0	(\$1.0)	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Net Income from Continuing Operations Available to Common Shareholders, GAAP	\$418.0	\$598.0	\$3,201.0	\$406.0	\$288.0	\$342.0	\$328.1	\$1,364.1	\$319.3	\$312.0	\$317.5	\$351.1	\$1,299.9	\$1,457.7
Net Income from Discontinued Operations	\$1.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Net Income, GAAP	\$419.0	\$598.0	\$3,201.0	\$406.0	\$288.0	\$342.0	\$328.1	\$1,364.1	\$319.3	\$312.0	\$317.5	\$351.1	\$1,299.9	\$1,457.7
Basic Shares Outstanding	106.9	101.6	96.9	94.2	91.1	88.0	86.5	89.9	85.6	84.8	84.0	83.2	84.4	81.1
Effect of Dilutive Stock , Restricted Stock , Deferred Compensation Units, Convertible Instruments & Dividends on Preferred Stock	3.6	3.2	1.0	0.8	0.7	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0
Diluted Shares Outstanding	110.5	104.8	97.9	95.0	91.8	88.6	86.5	90.5	85.6	84.8	84.0	83.2	84.4	81.1
Basic EPS	\$3.84	\$6.01	\$33.02	\$4.31	\$3.16	\$3.89	\$3.80	\$15.16	\$3.73	\$3.68	\$3.78	\$4.22	\$15.41	\$17.98
Diluted EPS from Continuing Operations, Adjusted	\$6.80	\$6.98	\$11.88	\$4.36	\$4.02	\$3.70	\$4.02	\$16.10	\$3.73	\$3.68	\$3.78	\$4.22	\$15.41	\$17.98
Diluted EPS from Continuing Operations, GAAP	\$3.78	\$5.71	\$32.70	\$4.27	\$3.14	\$3.86	\$3.80	\$15.07	\$3.73	\$3.68	\$3.78	\$4.22	\$15.41	\$17.98
Diluted EPS, GAAP	\$3.79	\$5.71	\$32.70	\$4.27	\$3.14	\$3.86	\$3.80	\$15.07	\$3.73	\$3.68	\$3.78	\$4.22	\$15.41	\$17.98

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	A
Growth Score	A
Momentum Score	F
VGM Score	A

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless otherwise indicated in the report's first-page footnote. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.